Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Bio”), has recently launched an open, multi-queue, multi-center phase II clinical trial to evaluate the efficacy and safety of SYS6041 in combination therapy for recurrent ovarian cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.